For patients with metastatic castration-resistant prostate cancer whose tumors harbor BRCA1/2 alterations, the potential benefits of combining a PARP inhibitor and an androgen receptor pathway inhibitor for first-line treatment outweigh the potential side effects. Further research is required to identify patients without detectable BRCA1/2 defects who would benefit from this approach.
European urology focus. 2024 Sep 03 [Epub ahead of print]
Elena Castro
Department of Medical Oncology, Hospital Universitario 12 de Octubre, Madrid, Spain. Electronic address: .